Cerebral microbleeds in CADASIL

Cerebral Microbleeds: Pathophysiology to Clinical Practice

Volumn , Issue , 2011, Pages 135-141

  Viswanathan, Anand ^a   Chabriat, Hugues ^b   Dichgans, Martin ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HÔPITAL LARIBOISIÈRE   (France)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879212431     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511974892.018     Document Type: Chapter

References (44)

1. Tournier-Lasserve E, Joutel A, Melki J et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 1993;3:256-9.
2. Joutel A, Corpechot C, Ducros A et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10.
3. Dichgans M, Mayer M, Uttner I et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. AnnNeurol 1998;44:731-9.
4. Chabriat H, Vahedi K, Iba-Zizen MT et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995;346:934-9.
5. Chabriat H, Levy C, Taillia H et al. Patterns of MRI lesions in CADASIL. Neurology 1998;51:452-7.
6. Tournier-Lasserve E, Iba-Zizen MT, Romero N, Bousser MG. Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy. Stroke 1991;22:1297-1302.
7. Auer DP, Putz B, Gossl C et al. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology 2001;218:443-51.
8. O’sullivan M, Rich PM, Barrick TR, Clark CA, Markus HS. Frequency of subclinical lacunar infarcts in ischemic leukoaraiosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. AJNR Am J Neuroradiol 2003;24:1348-54.
9. van den Boom R, Lesnik Oberstein SA, Ferrari MD, Haan J, van Buchem MA. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages: 3rd-6th decades. Radiology 2003;229:683-90.
10. Lesnik Oberstein SA, van den Boom R, van Buchem MA et al. Cerebral microbleeds in CADASIL. Neurology 2001;57:1066-70.
11. Dichgans M, Holtmannspotter M, Herzog J et al. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke 2002;33:67-71.
12. Viswanathan A, Chabriat H. Cerebral microhemorrhage. Stroke 2006;37:550-5.
13. Lee YC, Liu CS, Chang MH et al. Population-specific spectrum of NOTCH3 mutations, MRI features and founder effect of CADASIL in Chinese. J Neurol 2009;256:249-55.
14. Viswanathan A, Guichard JP, Gschwendtner A et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain 2006;129:2375-83.
15. Ruchoux MM, Maurage CA. CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 1997;56:947-64.
16. Wong KS. Risk factors for early death in acute ischemic stroke and intracerebral hemorrhage: a prospective hospital-based study in Asia. Asian Acute Stroke Advisory Panel. Stroke 1999;30:2326-30.
17. Arboix A, Massons J, Garcia-Eroles L, Oliveres M, Targa C. Diabetes is an independent risk factor for in-hospital mortality from acute spontaneous intracerebral hemorrhage. Diabetes Care 2000;23:1527-32.
18. Passero S, Ciacci G, Ulivelli M. The influence of diabetes and hyperglycemia on clinical course after intracerebral hemorrhage. Neurology 2003;61:1351-6.
19. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4.
20. de Courten-Myers GM, Kleinholz M, Holm P et al. Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med 1992;21:120-6.
21. Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-1701.
22. Kase CS, Furlan AJ, Wechsler LR et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001;57:1603-10.
23. Meigs JB, Mittleman MA, Nathan DM et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000;283:221-8.
24. Demchuk AM, Morgenstern LB, Krieger DW et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34-9.
25. Bruno A, Levine SR, Frankel MR et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002;59:669-74.
26. Song EC, Chu K, Jeong SW et al. Hyperglycemia exacerbates brain edema and perihematomal cell death after intracerebral hemorrhage. Stroke 2003;34:2215-20.
27. Tsukada K, Sekizuka E, Oshio C, Minamitani H. Direct measurement of erythrocyte deformability in diabetes mellitus with a transparent microchannel capillary model and high-speed video camera system. Microvasc Res 2001;61:231-9.
28. Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 1993;24:111-16.
29. Gridley T. Notch signaling in vascular development and physiology. Development 2007;134:2709-18.
30. Joutel A, Andreux F, Gaulis S et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 2000;105:597-605.
31. Domenga V, Fardoux P, Lacombe P et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004;18:2730-5.
32. Schweisguth F. Regulation of notch signaling activity. CurrBiol 2004;14:R129-38.
33. Oberstein SA, Ferrari MD, Bakker E et al. Diagnostic Notch3 sequence analysis in CADASIL: three new mutations in Dutch patients. Dutch CADASIL Research Group. Neurology 1999;52:1913-15.
34. Joutel A, Vahedi K, Corpechot C et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 1997;350:1511-15.
35. Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004;127:2031-8.
36. Peters N, Opherk C, Zacherle S et al. CADASIL-associated Notch3 mutations have differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. Exp Cell Res 2004;299:454-64.
37. Haritunians T, Chow T, de Lange RP et al. Functional analysis of a recurrent missense mutation in Notch3 in CADASIL. J Neurol Neurosurg Psychiatry 2005;76:1242-8.
38. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling pathway. Am J Hum Genet 2004;74:338-47.
39. Karlstrom H, Beatus P, Dannaeus K et al. A CADASIL-mutated Notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Proc Natl Acad Sci USA 2002;99:17119-24.
40. Low WC, Santa Y, Takahashi K, Tabira T, Kalaria RN. CADASIL-causing mutations do not alter Notch3 receptor processing and activation. Neuroreport 2006;17:945-9.
41. Opherk C, Duering M, Peters N et al. CADASIL mutations enhance spontaneous multimerization of NOTCH3. Hum Mol Genet 2009;18:2761-7.
42. Monet-Lepretre M, Bardot B, Lemaire B et al. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Brain 2009;132:1601-12.
43. Viswanathan A, Godin O, Jouvent E et al. Impact of MRI markers in subcortical vascular dementia: a multi-modal analysis in CADASIL. Neurobiol Aging 2010;31:1629-36.
44. Liem MK, Lesnik Oberstein SA, Haan J et al. MRI correlates of cognitive decline in CADASIL: 7-year follow-up study. Neurology 2009;72:143-8.